CFO Jack Anders Sells Shares of Revolution Medicines

On June 16, 2026, Jack Anders, the Chief Financial Officer of Revolution Medicines, Inc. (NasdaqGS: RVMD), sold 2,722 shares of the company in a planned transaction. The shares were sold at an average price of $156.12, amounting to a total value of $424,958.64.

Insider Buying and Selling at Revolution Medicines, Inc.

Several insiders at Revolution Medicines executed planned sales on June 16, 2026. Alongside CFO Jack Anders, President of Research and Development Stephen Michael Kelsey sold 4,175 shares, and General Counsel Jeff Cislini sold 2,157 shares, both at the same average price of $156.12. CEO Mark Goldsmith also sold 10,020 shares, while Chief Global Commercialization Officer Anthony Mancini sold 4,615 shares, and Chief Operating Officer Margaret Horn sold 29,600 shares on June 17, 2026, at an average price of $160.12.

Other Institutional Activity in Revolution Medicines

Among institutional investors, Farallon Capital Management reduced its stake by 978,000 shares, leaving it with 13,604,796 shares valued at approximately $1.32 billion. BlackRock, Inc. increased its holdings by 2,286,050 shares, reaching 11,212,706 shares worth about $1.09 billion. Janus Henderson Group PLC cut its position by 2,537,006 shares, bringing its total to 9,766,496 shares valued at $949.54 million. Baker Bros. Advisors LP added 100,000 shares, for a total of 9,555,357 shares worth $929.26 million. FMR LLC trimmed its holdings by 123,667 shares, leaving it with 8,464,314 shares valued at $823.15 million.

Revolution Medicines, Inc. Stock Down 24.1%

Shares of Revolution Medicines, Inc. traded near $157.77, with a market capitalization of approximately $33.54 billion. The company's stock has a 52-week low of $34.00 and a high of $166.50. It has a 50-day moving average of $145.17 and a 200-day moving average of $94.56. Revolution Medicines has a beta of 1.407, indicating moderate volatility compared to the broader market. The company is not currently profitable, as reflected by its negative forward P/E ratio of -27.66.

Analysts Set New Price Targets

Analysts have been active in setting price targets for Revolution Medicines. On June 10, 2026, Evercore ISI Group maintained a buy rating with a target price of $220. RBC Capital kept its buy rating on June 2, 2026, with a target of $182. HC Wainwright & Co. and Oppenheimer both maintained their buy ratings on June 1, 2026, with a target of $195 each. The consensus among analysts is a strong buy, with an average target price of $187.29 based on 21 analyst opinions.

About Revolution Medicines

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for RAS-addicted cancers. Based in Redwood City, California, the company specializes in RAS(ON) inhibitors and RAS companion inhibitors aimed at treating various solid tumors. Led by CEO Dr. Mark A. Goldsmith, the company employs 883 people and is advancing its clinical-stage pipeline to address significant unmet needs in oncology.

Bottom Line

Jack Anders' recent sale of shares in Revolution Medicines is part of a planned series of insider transactions. The company remains a focal point for investors due to its innovative approach in the biotechnology sector. Its stock performance, along with institutional and analyst activities, continues to attract attention. As always, remember that insider transactions and 13F filings reflect past actions and do not necessarily indicate future performance.